Active Biotech AB Year-end report January - December 2015

Laquinimod
· In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod's potential for treatment of primary progressive multiple sclerosis (PPMS)
· In June, it was announced that the company was to focus its operations on the laquinimod projects and adjust the organization accordingly
· In June, it was announced that the Phase 3 laquinimod study CONCERTO was fully enrolled
· In October, Teva presented data concerning laquinimod for the treatment of multiple sclerosis at the ECTRIMS congress
· The high dose group in the clinical studies CONCERTO, ARPEGGIO and LEGATO has been discontinued due to cardiovascular events
· The study results from both the pivotal clinical Phase 3 study CONCERTO in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017

Tasquinimod     
· In April, it was announced that Active Biotech and Ipsen were to discontinue development of tasquinimod for the treatment of prostate cancer
· The final results from the 10TASQ10 study were presented in September 2015 at the ECC conference and demonstrated that while the primary endpoint was reached and tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS

ANYARA, Paquinimod (57-57) and ISI
· Out-licensing activities are continuing

Financial summary

For further information, please contact: 
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
  
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
      

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
                                                                 
The report is also available at www.activebiotech.com.